What are Regeneron Pharmaceuticals's profit margins?

Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.

Where do Regeneron Pharmaceuticals's ratios come from?

Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Regeneron Pharmaceuticals REGN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Operating margin	105.1%-10.1pp	115.1%-17.9pp	133.1%-54.6pp	187.6%-20.5pp
Net margin	126.8%+0.7pp	126.2%-2.2pp	128.4%-34.5pp	162.8%-32.7pp
EBITDA margin	119.6%-9.0pp	128.6%-16.9pp	145.5%-51.1pp	196.6%-20.1pp
Free cash flow margin	107.2%+0.9pp	106.3%-20.7pp	127%-49.7pp	176.7%—
Returns
Return on equity	61.4%-3.6pp	65%-7.0pp	72%-58.2pp	130.2%-59.6pp
Return on assets	47.8%-2.9pp	50.8%-5.0pp	55.7%-40.4pp	96.1%-35.4pp
Return on invested capital	45%-10.1pp	55.1%-13.9pp	69%-64.6pp	133.6%-41.1pp
Efficiency
Asset turnover	1.5×-0.1×	1.6×-0.1×	1.7×-0.6×	2.3×-0.4×
Liquidity
Current ratio	17.7×-3.0×	20.7×-1.1×	21.8×+1.5×	20.3×+6.3×
Quick ratio	14.5×-3.1×	17.5×-1.2×	18.7×+1.4×	17.3×+5.6×
Cash ratio	2.7×+0.2×	2.5×-0.8×	3.3×-1.2×	4.5×+1.8×
Leverage
Debt-to-equity	0.4×0.0×	0.4×-0.1×	0.4×-0.1×	0.5×-0.2×
Debt-to-assets	0.3×0.0×	0.3×0.0×	0.3×0.0×	0.4×-0.1×
Net debt / EBITDA	0.1×-0.4×	0.5×+0.4×	0×+0.4×	-0.4×-0.6×
Interest coverage	354.4×+107×	247.8×+2.2×	245.6×-231×	477×+35.7×
Per Share
Book value per share	$1,116.56+13.2%	$986.32+14.0%	$865.02+15.8%	$747.30+32.6%
Valuation
Market capitalization	$266.44B-34.9%	$408.97B+18.4%	$345.41B+17.3%	$294.4B+20.7%
Enterprise value	$266.78B-35.1%	$410.99B+18.9%	$345.53B+18.4%	$291.83B+19.2%
Price / earnings	59.1×-36.2×	95.3×+10.9×	84.4×+31.3×	53.1×+13.0×
Price / sales	18.7×-11.3×	30×+3.1×	27×+5.9×	21.1×+1.7×
Price / book	8.8×-5.6×	14.4×+0.4×	14×+0.1×	13.9×-1.7×
EV / EBITDA	62.9×-30.8×	93.7×+19.4×	74.4×+30.7×	43.7×+7.0×
EV / sales	18.8×-11.4×	30.2×+3.2×	27×+6.1×	20.9×+1.4×
Free cash flow yield	23.4%+8.9pp	14.6%-4.4pp	19%-16.0pp	35%—
Earnings yield	27.6%+10.4pp	17.3%-1.9pp	19.2%-12.7pp	31.9%-8.9pp
Dividend yield	1.4%—	0%—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Regeneron Pharmaceuticals's profit margins?: Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
Where do Regeneron Pharmaceuticals's ratios come from?: Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.